Jason Campagna
Company: Q32 Bio
Job title: Chief Medical Officer
Seminars:
The Clinical Promise of Tissue Targeted Complement Therapeutics 10:40 am
Exploring Q32’s approach in utilizing tissue targeted therapies for complement mediated diseases ADX-097’s ability to block complement activity whilst persevering natural immune responses Exploring the benefits and the future promise of tissue targeted therapeutics in the complement industry.Read more
day: Conference Day Two